ArticleCancer medicine2021
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
Jie Zhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this papercites it